Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Apr 29, 2015
SAN DIEGO, April 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor currently in development for the treatment of pain and potentially fibrotic diseases. T...
Apr 10, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, Calif., April 10, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as comp...
Apr 9, 2015
SAN DIEGO, April 9, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015, at 12:50 p.m. Eastern Time (9:50 a.m. Pacific Time), at the Westin Grand Central Hotel in New York...
Apr 7, 2015
SAN DIEGO and WOODCLIFF LAKE, N.J., April 7, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc., announced today that the US Patent and Trademark Office granted Arena US Patent No. 8,999,970, which describes a method for selecting appropriate patients based on renal function for BELVIQ® (lorcaserin HCl), a serotonin...
Mar 2, 2015
SAN DIEGO, March 2, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2014. "2014 was a pivotal year for Arena, marked by the advancement of multiple development programs and the growth of sales of BELVIQ," s...
Feb 23, 2015
SAN DIEGO, Feb. 23, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, March 2, 2015, to provide a corporate update and discuss fourth quarter and full year 2014 financial results. Arena will release its financi...
Feb 18, 2015
SAN DIEGO, Feb. 18, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 2015 RBC Capital Markets Healthcare Conference on Tuesday, February 24, 2015, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at The New York Palace Hotel in New Yor...
Feb 3, 2015
SAN DIEGO, Feb. 3, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Ildong Pharmaceutical Co., Ltd., has informed Arena that the Ministry of Food and Drug Safety has approved BELVIQ® (lorcaserin HCl) for marketing for weight management in South Korea. Ildong will market and distribute BELVIQ in South Korea u...
Feb 2, 2015
SAN DIEGO, Feb. 2, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time), at The Waldorf Astoria in New York City. ...
Jan 21, 2015
SAN DIEGO, Jan. 21, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has sold 21,000,000 shares of common stock to Jefferies LLC and Piper Jaffray & Co. as underwriters for its previously announced public offering. The underwriters offered the shares to purchasers in transactions on The NASDAQ Global Select Ma...
Jan 20, 2015
SAN DIEGO, Jan. 20, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares are being offered by Arena. Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.  ...
Jan 12, 2015
SAN DIEGO, Jan. 12, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient dosing in a Phase 2 clinical trial of ralinepag, an oral, non-prostanoid prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). "An intriguing component of this compoun...
Jan 9, 2015
SAN DIEGO, Jan. 9, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported on Eisai Inc.'s updated BELVIQ® marketing program with targeted new initiatives to address payers, patients and physicians. Encouraged by the increasing number of payers who have made the decision to provide formulary coverage for BELVIQ, E...
Jan 7, 2015
SAN DIEGO, Jan. 7, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from a Phase 1b multiple ascending dose clinical trial for APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases. In the Phase 1b cl...
Jan 6, 2015
SAN DIEGO, Jan. 6, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015, at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time), at The Westin St. Francis Hotel in San Fr...
Page: First Previous
...
...
Next Last
 
= add release to Briefcase